Laura Blakely, MD
Hematology & Oncology · Hermitage, TNNPI 1265464499
Payments from drug & device makers
Across 119 payments — averaging $18,874 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$979K
- Siemens Medical Solutions USA, Inc.$908K
- Merck$247K
- Varian Medical Systems, Inc.$72K
- Sobi, Inc$29K
- Novartis$8K
- plus $3K from 31 others
Across 5 payments — averaging $548.66 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- F. Hoffmann-la Roche AG$2K
- Novartis$602
What the payments were for
- Consulting fees$2,36340%
- Speaking & faculty fees$1,14420%
- Food & beverage$2,26939%
- Education$741%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 3 | $978,764 |
| Siemens Medical Solutions USA, Inc. | 13 | $908,469 |
| Merck | 13 | $247,308 |
| Varian Medical Systems, Inc. | 3 | $71,895 |
| Sobi, Inc | 2 | $29,015 |
| Novartis | 15 | $7,575 |
| Bristol Myers Squibb | 4 | $1,197 |
| CSL Behring | 7 | $203 |
| Genentech USA, Inc. | 5 | $194 |
| Gilead(2 entities) | 2 | $159 |
| Foundation Medicine, Inc. | 1 | $121 |
| Daiichi Sankyo Inc. | 5 | $120 |
| Sanofi | 2 | $105 |
| E.r. Squibb & Sons, L.L.C. | 6 | $96 |
| Eisai Inc. | 3 | $69 |
| Pfizer | 5 | $65 |
| AbbVie | 2 | $61 |
| Teva Pharmaceuticals USA, Inc. | 3 | $60 |
| Johnson & Johnson | 2 | $47 |
| Lexicon Pharmaceuticals, Inc. | 2 | $42 |
| Mirati Therapeutics, Inc. | 2 | $42 |
| Karyopharm Therapeutics Inc. | 1 | $41 |
| Pharmacyclics LLC, An Abbvie Company | 2 | $39 |
| Regeneron Healthcare Solutions, Inc. | 2 | $38 |
| Dendreon Pharmaceuticals LLC | 1 | $35 |
| Lilly USA, LLC | 2 | $27 |
| Array Biopharma Inc | 1 | $27 |
| Bayer | 1 | $23 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $22 |
| Genmab U.S., Inc. | 1 | $22 |
| AVEO Pharmaceuticals, Inc. | 1 | $20 |
| Biocompatibles, Inc. | 1 | $20 |
| Amgen | 1 | $17 |
| Verity Pharmaceuticals Inc. | 1 | $15 |
| Rigel Pharmaceuticals, Inc. | 1 | $14 |
| Taiho Oncology, Inc. | 1 | $13 |
| Incyte Corporation | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- KISQALI$2,363
- Yescarta$147
- FOUNDATIONONE$121
- FOUNDATIONONE HEME$121
- FOUNDATIONONE CDX$121
- FOUNDATIONFOCUS$121
- FOUNDATIONONE LIQUID CDX$121
How this compares
$2,245,991 in reported general payments places this provider in the 85th percentile of 251 hematology & oncology providers in Tennessee.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| RevlimidLenalidomide | 43 | $558,226 |
| IbrancePalbociclib | 28 | $405,808 |
| CalquenceAcalabrutinib Maleate | 24 | $291,382 |
| ImbruvicaIbrutinib | 14 | $202,056 |
| Imatinib Mesylate | 15 | $37,999 |
| Abiraterone Acetate | 16 | $7,299 |
| EliquisApixaban | 11 | $6,117 |
| Anastrozole | 169 | $2,818 |
| Prochlorperazine Maleate | 82 | $1,415 |
| Letrozole | 67 | $1,244 |
| Ondansetron OdtOndansetron | 62 | $1,154 |
| Tamoxifen Citrate | 27 | $1,110 |
| ValacyclovirValacyclovir Hcl | 15 | $806 |
| Dexamethasone | 40 | $682 |
| Hydroxyurea | 21 | $472 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Bristol Myers SquibbRevlimid | $1,197 | $558,22643 claims |
| PfizerIbrance, Eliquis | $65 | $411,92539 claims |
| AstraZenecaCalquence | $978,764 | $291,38224 claims |
| Pharmacyclics LLC, An Abbvie CompanyImbruvica | $39 | $202,05614 claims |
| Teva Pharmaceuticals USA, Inc.Acyclovir | $60 | $33036 claims |
| Lilly USA, LLCOlanzapine | $27 | $15642 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 251 hematology & oncology providers in Tennessee.
Other hematology & oncology in Hermitage
- Erika HamiltonNashville$45.4M
- Ian FlinnNashville$41.2M
- Johanna BendellNashville$28.5M
- Jesus BerdejaNashville$22.2M
- Meredith McKeanNashville$16M
- Krish PatelNashville$14.2M
- Kathryn BeckermannFranklin$13.6M
- Denise YardleyNashville$13.2M
- Todd BauerNashville$10.9M
- Bertrand AnzChattanooga$9.6M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.